StartUps and SMEs
Kanaph Therapeutics and IMbiologics launched successful offerings in the IPO-scarce Korean market in the first quarter, as investors become more selective in their targets.
San Diego-based Onchilles Pharma's neutrophil-derived ELANE pathway agent N17350 targets a universal cancer vulnerability, combining direct tumor killing with immune activation. It is now entering first-in-human trials across solid tumors.
As immune-system science attracts record capital and scientific talent, five companies at the vanguard of the field reveal a shared conviction: the immunome is the organizing principle of human health. The harder question is how to build a business around it.
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
The company’s next VC round hinged on Phase I results for QRL-201, an antisense oligonucleotide designed to restore STMN2 expression in ALS patients, and topline data are promising.
NextGate Partners’ managing partner shares his views on the biopharma investment and dealmaking environment in South Korea, along with the particular strengths of companies in the country and R&D areas of focus for this year.
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
Private Company Edition: Santé raised a new $330m life science and health care-focused VC fund, while Gimv said it will not back any new life science opportunities. Also, Angitia raised a $130m series D round, QuantX closes a $35m series B and other financings.
SpliSense is the first company to show inhaled antisense oligos improve lung function in cystic fibrosis, validating its platform for larger COPD and asthma markets.
Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.
The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.